Actinium Pharmaceuticals Stock Price To Earnings To Growth
| ATNM Stock | USD 1.44 0.03 2.13% |
Actinium Pharmaceuticals fundamentals help investors to digest information that contributes to Actinium Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Actinium Stock. The fundamental analysis module provides a way to measure Actinium Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Actinium Pharmaceuticals stock.
Actinium | Price To Earnings To Growth |
Actinium Pharmaceuticals Company Price To Earnings To Growth Analysis
Actinium Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Actinium Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Actinium Pharmaceuticals is extremely important. It helps to project a fair market value of Actinium Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Actinium Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Actinium Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Actinium Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Actinium Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Actinium Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Actinium Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actinium Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actinium Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Actinium Pharmaceuticals by comparing valuation metrics of similar companies.Actinium Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
Actinium Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Actinium Pharmaceuticals from analyzing Actinium Pharmaceuticals' financial statements. These drivers represent accounts that assess Actinium Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Actinium Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 32.5M | 94.6M | 123.6M | 257.1M | 135.1M | 86.5M | |
| Enterprise Value | 24.7M | 31.8M | 46.1M | 150.8M | 60.6M | 77.2M |
Actinium Fundamentals
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (576.65) % | ||||
| Current Valuation | (31.71 M) | ||||
| Shares Outstanding | 31.2 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 30.10 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 543.04 X | ||||
| Revenue | 81 K | ||||
| Gross Profit | 1.03 M | ||||
| EBITDA | (51.13 M) | ||||
| Net Income | (48.82 M) | ||||
| Cash And Equivalents | 116.33 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 2.11 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 18.83 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (47.34 M) | ||||
| Short Ratio | 5.72 X | ||||
| Earnings Per Share | (1.39) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 49 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 43.99 M | ||||
| Total Asset | 81.44 M | ||||
| Retained Earnings | (337.58 M) | ||||
| Working Capital | 69.77 M | ||||
| Current Asset | 26.48 M | ||||
| Current Liabilities | 4.61 M | ||||
| Net Asset | 81.44 M |
About Actinium Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actinium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actinium Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actinium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Actinium Pharmaceuticals Piotroski F Score and Actinium Pharmaceuticals Altman Z Score analysis. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.